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Improvements in immunosuppression and recipient selec- 
tion have been associated with .&eased short- and long- 
term survival rates with heart ransplantation. A number of 
compkations, however, do occur after heart ra~s~~antatio~ 
(I), most of which can be traced to relative inadequate or
excessive dosing or intrinsic properties of immunosuppres- 
sive medications. The following section is a brief overuiew 
of these complications. 
42 MILLER ET AL. 
TASK FORCE 5 
JACC Vol. 22, No. 1 
July 1993:1-64 
Early Pustogerative Cmnp!ications 
Primary graft failure is the earliest potential complication 
following cardiac transplantation a d is usually evident in 
the operating room. It is largely related to donor selection 
a9d, although frequently reversible, patients may require 
mechanical support or even retransplantation. Such graft 
failure is quite uncommon today because of universally 
stringent donor selection criteria. Another early periopera- 
tive complication is right ventricular failure secondary to 
high pulmonary vascular esistance in the recipient. This 
problem can usually be avoided by careful screening ofthe 
potential recipient before transplantation and periodic reas- 
sessment of transpulmdnary pressures and resistance while 
on the waiting list. Treatment ofreversibly elevated pulmo- 
nary vascular esistance (>3 to 4 Wood units) includes 
intravenous e of prostaglandins or other potent vasodila- 
tori inotropic drugs (2). Irreversible pulmonary hypertension 
and consequent right heart failure remain one of the leading 
causes of very early mortality in heart ransplant recipients 
(2,3) despite fforts to screen out recipients with irreversibly 
elevated pressures. 
Many patients require temporary pacing support for the 
1st 3 to 7 days after transplantation. However, 2% to 10% of 
patients will require a permanent pacemaker because of 
dysfunction or block of the sinus or atrioventricular (AV) 
node, or His bundle conduction system (4,5). Agents uch as 
theophylline or terbutaline may enhance ventricular re- 
sponse and delay or obviate the need for permanent pacing, 
especially inpatients receiving amiodarone b fore transplan- 
tation. 
ejeetio 
Cardiac allograft rejection is the natural response of the 
host to foreign alloantigen that, left untreated, ultimately 
leads to allograft destruction. Despite the number of ad- 
vances in immunosuppression and strategies designed to 
treat rejection, it remains one of the leading causes of death 
in the first year after heart ransplantation (3,6-l 1). 
Cardiac rejection had traditionally been classified func- 
tionally into hyperacute, acute and chronic types. However, 
with developments leading to E better un&&rstanding of the 
immunologic mechanisms involved, in recent years cardiac 
rejection has been reclassified as either cell mediated (the 
most common form of acute rejection) or antibody mediated 
(often referred to as humoral or vascular rejection), which is 
much less common. Chronic rejection is the term previously 
used to describe allograft coronary artery disease, but it is a 
misnomer because most investigators agree that his form of 
vasculopathy is not actually atype of rejection. 
Acute Rejection 
Characteristics of asute rejection. Although the definition 
o? rejection varies, one operational definition that has been 
used by the Transplant Cardiologists Research Database 
(TCRD) (7) includes any clinical event-usual?y, but not 
invariably, accompanied by abnormal endomyocardial bi- 
opsy findings-that is treated with significant a~grne~tat~o~ 
of immunosuppression. As assessed by this definition in 
patients, the mean cumulative number of rejection episodes 
at 1 year was 1.3 of: 0.7 rejection episodes per patient. 
According to the TCRD data, 37% of patients had no 
rejection episode, 40% had one episode and 23% had more 
than one episode in the 1st year after transplantation. The 
majority of all rejection episodes were asymptomatic and 
occurred within 6 months of transplantation. 
counted for 17% of all deaths in the TC 
observation similar to that of other ecent rep 
International Society for Heart and Lung Transplantation 
(ISHLT) Registry (6) has reported that rejection accounted 
for 30% of all deaths during the past decade, but this 
percentage also included deaths m allograft coronary 
disease, which was previously cod s a form of rejection. 
Risk Factors 
Many factors have been variably reported to be associ- 
ated with an increased risk of rejection including human 
leukocyte antigen (HLA) mismatch (12), female gender (13), 
young age (14), non-0 blood types (15), female and younger 
donor hearts (7), panel reactive antibody screen >lO% 
(16,17), positive donor specific rossmatch (15), 0KT3 mu- 
sine monoclonal ntibody sensitization (17), cytomegalovi- 
rus infection (18) and the presence of anti- 
(19). However, rejection risk data from single institutions 
must be viewed carefully because patient numbers are small 
and the incidence varies with threshold to treat rejection, 
Large multi-institutional studies (7,20) suggest that female 
gender, HLA mismatches and fern& or younger donor 
hearts constitute the highest risk factors. 
The multiparous female heart ransplant recipient appears 
to be at high risk for antibody-mediated rejection because of 
possible sensitization that may have occurred at the time of 
pregnancy (12). The reason that female or younger donor 
hearts are risk factors for rejection is speculative. 
Diagnosis of Rejection 
Since the introduction of the endomyocardial biopsy by 
Caves et al. (21) in 1973, ithas been considered the reference 
standard for the detection of cardiac rejection and assess- 
ment of the adequacy of antirejection therapy. In 1989, 
cardiac pathologists from several heart transplant centers 
met and formulated the ISHLT scale for standardizing the 
grade of cardiac rejection on the endomyocardial biopsy 
specimen (Table 1) (22). There are some iimitations to the 
endomyocardial biopsy standard and these include sampling 
error, biopsy-induced artifact and vxiability d &rpreta- 
tion despite the standardized scale. Surveillance biopsies 
usually are performed frequently during the 1st 6 months ” 
after transplantation because of the high incidence of rejec- 
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. iogsy the rrlg IISHLT Scale,i E) 
._I_ --- - 
Grade “New” Nomewlature 
--it 
--.. -- 
No rejection No rejection 
I 1 = fcml (perivaxular oh interstitiat) infiltrate without necrosis Mild rejection 
I& = diffuse but sparse infiltrate withfiut necrosis 
2 One focus only viith aggressive infiltration andior focal “FQcal” moderate rejection 
myocyte damage 
3 3A = multifocal aggressive islfiltrates and/or myacyre damage “Low” moderate rejection 
38 = diffuse inflammatory process with necrosis “Borderline/severe” 
4 Diffuse aggressive polymorphous t infiltrate -C edema. 2 “Severe acute” rejection 
hemorrhage. f vasculitis, with necrosis 
PSHLT = International Society of Heart and Lung Transplantation. 
tion during that period, and they 
quently thereafter. The exact regime 
biopsies varies from center to center. 
Because n&myocardial biopsy is an invasive and ex- 
pensive procedure, Ihorc: 1~ jeen an intensive search for an 
accurate and reprodu:thl:r nowinv 
acute rejection. Nonin~rpsive re hn 
icated on the detection of a physiologic abnormality of the 
rejecting heart (23-3 I ) (that is, myocardiai edema) or the 
detection of some aspect of immune system activation 
involved in the rejection process (32-39) (Table 2). Unfortu- 
nately, no methodology thus far investigated has achieved a
sensitivity or predictive accuracy high enough to replace the 
endomyocardial biopsy in the detection of rejection in 
adults. In children thet: tends to be greater eliance on 
noninvasivc techniques because of the obvious technical 
ditkulties and increased risk of obtaining requested endo- 
myocardial biopsy specimens. 
Tmmneiai Stra tegies fix ACUte &miim 
Despite standardization of interpretation f endomyocar- 
dial biopsies, the therapy of acute rejection remains varied 
and individualized (41). The choice of therapy may depend 
not only on histobgic grade of rejection, but also on clinical 
symptoms, hemodynamic changes, noninvasive ( chocar- 
diographic) Endings, and time after transplantation, as well 
as on the experience ofthe clinician. Generafly, mild rejec- 
tion is not believed to warrant active treatment, although it
may progress to higher grades of rejection in 18% to 33% of 
subsequent endomyocardial biopsies (42-44) and does war- 
rant careful short-term follow-up. 
There is general consensus that the presence of 
lymphocytic Infihrates with myocyte necrosis as in 
grade 3,4 (moderate orsevere) rejection En ths endomyocar- 
dial biopsy specimert epresents significant graft rejection 
and does warrant augmentation f immunosuppression. The
traditional method of therapy for asymptomatic ISMLT 
pde 3,4 rejection has been the use of high dose corticos- 
teroids, either intravenous ororal (43-45). Doses range from 
1,500 to 3,000 mg of methylprednisolone i travenously (di- 
vided over 3 days) or 300 to 1,OUO mg of prednisone orally 
(tapered over 7 to 14 
lower doses may be 
that fail to resolve with a second course of high dose 
corticosteroids or that present with significant bemody~am~c 
compromise are usually treated wit 
persistent or intractable r jection have been under iuvesti- 
gation. These include low dose metbotrexate (5 I ,52), myco- 
T&k 2. Classification of Noninvasive Methoc$s Prqxxeb to 
Detect Cardiac Rejection 
I. Detection fphysio[opic properties of the rejecting he& 
A. Clinical findings 
B. Eiectrocardiographyielectrophysiolog~ 
I. ECG voltage 
2. Intramyocardial electrogram 
3. Signs!-averaged ECG 
4. Abnormalirk of !he cooduc!ion synea 
t. F&cardiography 
1. Left ventricular dimensions. volumes. cystok function 
2. DOpplCi indexes of diasSolic function (isovalumetric Iclaxation 
time. pressure half-time) 
D. Nuclear magnetic resonance imaging 
1. T, r&x&ion rime 
2. Lef! ventricular dimensions 
E. Nuc!ear scintigraphy 
!, Technetium-99m. technetium-99m pyrophosphate. tha!!!um-201. 
gallium-67 
2. Indium-I I I-labeled antimyosin antibodies 
Il. Activation of the immune system 
A. Cytoimmunologic monitoring ICIMI 
I. Activated lymphocytes 
2. E-rosette assay 
3. T&T8 ratio 
4. Deoxyribonucleic acid (DNAI analysis 
B. Other immtmologis markers 
I. Interleukin-2 receptors 
2. Transferrin receptors 
3 Meopterin 
4. Serum probctin 
5. Beta-Z microglobulins 
6. Dipeptidyl peptidate IV 
7. Urinary polyamines 
g. iumor necrosis factor 
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phenolate mofetil (RS-61443) (53), FK-506 (54), total lym- 
phoid irradiation (55) and photochemotherapy (56). These 
newer forms of therapy are discussed inmore detail in Task 
Force 6. In rare cases, despite aggressive immunosuppres- 
sion, acute rejection will progress to allcgraft destruction. 
Humoral Rejection 
Unlike cellular rejection, which can be diagnosed by 
routine hematoxylin-eosin staining and light microscopy, the 
diagnosis of humoral rejection is based on both light and 
immunofluorescent staining of biopsy specimens (57,58). 
Immunofluorescence findings include the deposition of im- 
munoglobulin a d complement onthe vascular endothelium 
plus evidence of endothelia! cell swelling and activation on 
routine staining. The antibodies (immunoglobulin) have 
specificity for donor HLA class II antigens on the endothe- 
lium althougit non-HLA antigens may also be a target for 
antibody-mediated injury. Vascular ejection has been re- 
ported to occur in 15% to 20% of heart ransplant patients 
receiving antilymphocyte prophylaxis (!8). Humoral rejec- 
tion has been associated with a higher incidence of fata! 
rejection (12), development of transplant coronary artery 
disease (59-61) and a decreased long-term survival (54-60). 
Some patients may have demonstrable immunogiobulin or 
complement, or both, on the endothelium but treatment is 
reserved for pa?iects Gth concomitant hemodynamic com- 
promise. In general, no treatment is believed to be required 
for isoiated humora! rejection unless there is concomitant 
cardiac allograft dysfunction, inwhich case high dose corti- 
costeroids, autithymocyte globulin (62), cyclophosphamide, 
and plasmapheresis (63) have been used with variable SW 
cess. The specific role of new agents uch 1s rnycophenolate 
mofetil (RS-61443) or enhancement of maintenance therapy, 
or both, remains to be studied. 
Hyperacute r jection isanother form of humoral rejection 
that causes immediate postoperative cardiac dysfunction 
and it is due to preformed antibodies in the recipient, These 
antibodies are usually the result of previous exposure to 
human antigeas (Le., pregnancy orprevious blood transfu- 
sion) and are directed against antigens present on the donor 
heart. Patients with hyperacute r jection have a poor prog- 
nosis. 
Rejection Prophylaxis 
Regimens for maintenance immunosuppression have 
evokfed to the current “triple-drug” regimen, which in- 
clud :s cyclosporine, azathioprine and prednisone, mployed 
in m\>st centers. The use of a three-drug regimen isdesig&d 
to dec.-ease the toxicity of any one drug by allowing the use’ 
of!ln~~doses of several drugs without overlapping toxicity. 
Because !here is a greater isk of rejection early after 
transg!a?.stion (3,7), cyclosporine and prednisone are usu- 
a!!~ maintained athigher doses during this period of time, 
with planned tapering (and sometimes discontinuation) of 
prednisone later postoperatively. 
In addition to triple-drug maintenance therapy, some 
programs administer either monoclona! or polyclonal anti- 
lymphocyte sera as “induction therapy” in the immediate 
postoperative period. Many comparison studies (64-66) 
have shown variable results between the two types of 
antilymphocyte sera. The purposes ofadministering antilym- 
phocyte sera have included permitting delay in the adminis- 
tration of cyclosporine inpatients at high risk for postoper- 
ative renal failure, minimization of early doses of 
corticosteroids and enhancement of immunosuppression 
during clearance of donor antigen-bearing cells from the 
allograft to minimize sensitization to the allograft (67-70). 
This form of therapy has been dem~~~strated to delay the 
time to first rejection, but it has not reduced the overall 
frequency of rejection. Large randomized prospeciive tria!s 
are lacking to prove or disprove any long-term benefit of 
prophy!actic aniiiymphocyte s rum administered in the im- 
mediate postoperative p riod over that of standard triple- 
drug therapy (71-73) without such “induction” therapy. 
The use of currently availabile nonspecific immunosup- 
pressive medicaiions toprevent aliograft rejection aturally 
resu!ts in an increased risk of ir.fection. Newer and more 
selective immunosuppressive ag nts uch as cyclosporine 
have been associated with not only a reduction in both the 
severity of infection and death due to infection, but also a 
decreased number of a!! types of infections (1,74-82). Nev- 
ertheless, infection remains a leading cause of death after 
heart rairspiantation (1,80-83). 
As in the case with other areas reporting in the field of 
transplantation, variable definitions of infection and lack of 
uniform regimens used for infection prophylaxis have re- 
sulted in widely varied estimates ofthe incidence of infection 
after heart ransplantation. A multicenter review from the 
Transplant Cardiology Research Database (TCRD) (80), 
using restrictive criteria of reporting only infections treated 
with intravenous therapy or serious infection treated with 
oral therapy (such as herpes zoster), recently reported an 
incidence of 0.5 infection/patient by an average of 8.4 
months of follow-up in >700 patients who underwent trans- 
plantation between January 1990 and July 1991. Sixty-eight 
percent of patients were free of any infection, 21% had one 
infection and 11% had more than one infection during the 
follow-up period. The exclusion of clinically trivial infec- 
tions such as oral herpes virus and Candida infections may 
account for the low incidence in the TCRD series. 
There are two peak incidence periods for infectious 
complications after heart ransplantation. The ‘-early”’ pe- 
riod (within the 1st month of transplantation) is dominated 
by nosocomia!, often catheter-related, infections (80,84,85), 
with predominantly Staphylococcus species and gram nega- 
tive organisms. In contrast, he “late” period (2 to 5 months 
after transplantation) is dominated by opportunistic nfec- 
tions with organisms such as cytomegalovirus, pneumocys- 
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ous infections, which are often ent within the 
days after tra~s~la~tat~Q~. T 
within the 1st 14 to 20 days, bu 
1st 3 months after 
transmitted disease. 
as a risk factor, blat ~re~~erat~~~e UNOS status, age, previ- 
ous sternotomy and preoperative r
independent risk factors for i 
The lung has been the m 
heari transplant recipients (80,8l,90) foliowed by blood, 
urine, gastrointestinal tr ct and the sternal wound. ~Itb~~gb 
sternal wound i&ction occurred in only 7% sf patients in 
series (80), it was associated with 25% of the 
iatric patients may exhibit a higher incidence of 
and sinusitis as weI1 as the gastro~~testi~a~ 
manifestations of many childhood illnesses and treatment for 
these infections may complicate cycles 
A variety of modalities have been us 
specific infecticns in the Sii~y iX&lS after tZmsplantaiiiiii 
or after treatment of rejection (9l-98), although only py- 
rimethamine (96) and trimetho -sulfameth~xazole (9’7) 
plantation for pro 
s and pneumocystis, respectively. 
orbidity and mortality associated with cytomegalo- 
V) infection (99) and numerous approaches to 
s (92-96), CMV remained the most common sin- 
gle infection reported in the TCRD series (80). Placement of
a CMV-positive donor organ into a CMV-negative r cipient 
is the most important risk factor (80,99-101) for developing 
clinical CMV infection and carries a 25% to 40% risk of 
developing clinical CMV disease. Because ofthe large number 
of CMV serotypes, primary infection may also occur in sero- 
positive recipients receiving a CMV-positive donor heart, and 
reactivation f prior CMV infection in a seropositive recipient 
after introduction of immunosu~pression is a well known 
phenomenon. I  a recent prospective, randomized study, 
most potent ahd specific treatment so far available for C 
nciclovir (NO), did not decrease the incidence of 
infection when given for the first 4 weeks after 
transplantation in heart transplant recipients who had received 
OKT3 prophylaxis for the 1st 14 days after transplantation, but 
such administration diddecrease the incidence ofreactivation 
infection (94). 
An unusual accelerated farm of cot-0 
occurs in heart transplant recipients a
unique to cardiac allogr 
scans with agents uch as 
en far too unsensitive forclinica 
and cannot obviate the need for s~rve~la~ce 
(115). The reason for this insensitivity is most 
p~rna~~y to the diffuse nature of the disease. 
ing problem clinically is that the dene~atio~ that occurs 
routinely with heart ransplantation generaFly prevents any 
sensation of angina-like pain to signal the develo 
this disease. Some level of reinnervatio 
demonstrated in several 
pain (I 16), and it is probable that angina1 
ally occur in heart transplant recipients. 
failure, acute myocardial infarction an 
death, alone or in combination, are t 
presenting symptoms of this disease (I 17). 
The diagnosis of this disease critiques to be 
“normal” (IN). The 
disease is di&e, 
and obliteration f distal branch ves 
mal, focal, epicardial stenoses typical 
nary artery disease may also appear. In comparison 
nontransplant patients with typical atherosclerotic core 
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disease, patients with allograft coronary artery disease exhibit 
aller percentage of proximal epicardial stenoses, a 
higher percentage of distal total occlusions, and nearly total 
absence of collateral vessel formation (119). This lack of 
ssels is believed to be a reflection ofthe rapidity of 
and diffuseness of the disease. 
dlogmft coronary artery disease can develop 
nths after transplantation, theuse of an angiogram 
obtained 1year after transplantation as the reference base- 
line can be very misleading. In fact, Gao et a!, (120) have 
_demonstrated statistically significant reductions in lumen 
diameter between angiograms obtained within 3 weeks of 
transplantation and the standard 1year examination. As a 
result, many centers now perform the first coronary angio- 
gram within 2 to 4 weeks of the transplant procedure inan 
attempt to obtain true baseline measurements of lumen 
diameter, as well as to document any preexisting disease in 
the donor heart that might be erroneously ascribed to 
aliograft coronary disease in subsequent s udies. More re- 
cently, intravascular ultrasound has been investigated as an 
imaging modality in the coronary arteries of heart ransplant 
recipients (121,122). This promising technique allows a very 
reproducible ook at both actual umen diameter and the 
appearance and thickness of the intima and media without 
relying on potentially diseased vessels to use as baseline 
reference. Improved imaging will potentially allow investi- 
gators to define the true incidence and natural history of this 
disease and have the ability to design trials with new 
therapeutic interventions. 
The histologic appearance of the arteries with allograft 
coronary artery disease is remarkable for hyperplasia of
smooth muscle cells and macrophages that migrate into the 
expanded intima, with resultant lumen compromise 
(123,124). These changes are concentric, not eccentric as in 
nontransplant coronary artery disease and involve the entire 
Length of fhe vessel. Atheromatous plaques do appear in 
allograft coronary artery disease, but unlike nontransplant 
coronary artery disease, they are minimally calcified, more 
cellular and contain a higher quantity of lipids, especially 
cholesterol. Ulceration and thrombus formation are dis- 
tinctly unusual until very late in the disease. 
The pathophysiologic mechanisms involved in this dis- 
ease may be multiple, but several lines of data suggest that it 
is primarily an immune-mediated disease; the most convinc- 
ing of these is the selective involvement ofthe vascular bed 
of the allograft with sparing of other native vessels in the 
body. Attempts to correlate the incidence of cellular ejec-. 
tion with later development of allograft coronary artery 
disease have produced inconsistent results (110,125,126), 
although the analysis of rejection as a risk factor for core- 
nary artery disease has been severely impaired by the 
previous lack of a standardized biopsy grading system. A 
major ole of the humoral immune system in the genesis of 
this disease has been suggested by discovery of a strong 
correlation of both measurable circulating HLA &bodies 
(127) and humoral (antibody mediated) “rejection” (57) with 
development of coronary artery disease. Other factors that 
have been noted to be associated with an increased inci- 
dence of allograft coronary artery disease include HLA 
mismatch, primarily at the DR locus (125,126), hyperlipid- 
emia (128), obesity (129), and CMV infection (130,131). 
The histologic hanges that characterize coronary artery 
disease are not unique. They are almost identical to other 
forms of accelerated atherosclerosis uch as that seen in 
patients who develop early restenosis after percutaneous 
transluminal coronary an$oplasty (132) or restenosis in 
saphenous vein grafts. Vascular endothelial cell injury, 
whether caused by primarily immune or uon~mmuue factors, 
apparently results in au identical, but nonspecific 4’response 
to injury,” This wou!d suggest that endothelial cell injury, 
regardless of the etiology, with ihe aid of cofactors uch as 
cytokirnes and growth factors, may trigger the proliferation 
of smooth muscle cells and macrophages characteristic of all 
three types of “accelerated atherosclerosis” (132-135). Dem- 
onstration of the importance of these cotidctors has led to 
investigation f new approaches to treatment of this disease 
including the use of agents uch as monoclonai ntibodies 
directed against the cytokine receptor interleukin 2 (136), 
against intracellular dhesion molecules (137) and against 
growth factors uch as platelet-derived growth factor (138). 
Inhibitors of smooth muscle cell proliferation and migration 
such as low molecular weight heparin (139) and angiopeptin 
(140), asomatostatin analogue that inhibits insulin-like growth 
factor are also being investigated as therapeutic agents. Angio- 
peptin is now undergoing simultaneous clinical trials, one to 
prevent postangioplasty restenosis and the other to prevent the 
development of cardiac allograft vascular disease. The success- 
ful use of a single agent to prevent accelerated atherosclerosis 
with two widely divergent mechanisms of vascular injury 
would strongly support the nonspecific “response to injury” 
hypothesis. In addition, the role of vasodilator d ugs to alter 
vascular remodeling after endothelial njury is also being inves- 
tigated (141). 
Medical therapies used in an attempt to retard or inhibit 
this disease have included exercise, smoking cessation, 
blood pressure control, cholesterol-lowering drugs, anti- 
platelet and anticoagulant drugs (142), fish oil (143) and 
calcium blockers (144). Unfortunately, none of these have 
been shown to influence the clinical course of allograft 
coronary artery disease. The role of augmenting immuno- 
suppression as a means of altering the progression of this 
disease warrants further investigation. 
Coronary angioplasty has been used in transplant patients 
(145) with initial success and restenosis rates at I year similar to 
those of nontransplant pa ients. Because of the diffuse nature 
of coronary artery disease, many patients are not suitable 
candidates forangioplasty and the procedure must be viewed 
as primarily patiiative, although disease progression is clearly 
not uniform even once it is evident angiographically. 
The ‘only definitive form of treatment for advanced al- 
lograft coronary artery disease is retransplantation. The 
number of patients who have undergone r transplantation 
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onary artery disease. 
ever, the ~mc~dence and t 
its response to thera 
mors in tra~s~~a~t recipiems 
nontra~s~~aot popuiation. The cunent esti 
malignancy after heart ra~§~~a~tation is 1 
may become higher with the ever increasing long-term 
survival rates, especially in patients with previous malig- 
nancy (154). 
Cutaneous malignancy is the rrn~st ~cmmnw twos mm- 
ciated with use of azathioprine (l49,150), perha lated to 
the azathioprine metabclite, ~~trom~dazo~e, causes 
enhanced photosensitivity. Unlike nontransplant patients in 
whom basal cell cancers are the most common type of 
cutaneous malignancy, azathioprine use is assaciated with a 
2: 1 predominance of squamous cell over basal cell carcino- 
mas and is associated with more metastatic disease. A 
umque form of lymphoma, lso ivlllrlrulllJ rtiir..v rM=.W=brr&, P.&,d to ac ., 
posttransplant lympho~ro~~fcrat~ve disease (!, EQ58), is 
the most common tumor eported with cyclosporine-based 
immunosuppression. This tumor develops at a mean of 12 to 
s after transplantation, occurs most commonly 
inally and has a variable prognosis. The tumor is 
usually of B cell origin, and appears to be induced by the 
Epstein-Barr virus (159-162). One report has suggested that 
primary infection with Epstein-Barr virus after transpla~ta- 
tion results in higher morbidity compared with secondary 
infection or reinfection (155). 
One aspect of posttransplant lymphoproliferative disease 
that differentiates it from other types of malignancy is the 
relation to the intensity of i unosuppression. Data from the 
Cincinnati Transplant Tumor Registry (149) suggest that up to 
40% of patients with this disease will respond to reduction i
immunotherapy, although the amount of reduct 
has nearer been studied prospectively. There are few data to 
support he use of chemothempy or ~diatio~ therapy as 
first-line treatment for this disease, but there is anecdotal 
experience that high grade tumors or those showing no regres- 
sion with decreased immunosuppression may show good re- 
sponse to aggressive chemotherapy (161). Use of both 0KT3 
ages of all medications pleed to be altered in pediatric 
patients to avoid Uiider or over-dosing. 
chronic qrcfnsp~~e 
becarrse f the effects on renal function of possible concom- 
itant rejection. Thus, there is only limited ~~ormatio~ re-
>arding the cmp:;;E:- m~rh&canc “KW”..‘_ . ..__.I. /*.I”.*.&. of rena! 
Lip-term consequences in heart ran 
injury and its 
mechanisms of cyclosporine associat 
multifactorial, but are la elated to renal vasoconstric- 
tor effects, primarily of arterioles, with er 
coflt~but~on of direct u icity (165-167). o- 
constrictor effect is manifest by a marked increase in rend 
vascular resistance and decreased renal blood Bow. 
mediators of the vasoconst~ct~om include prosta 
(!74) and en$othelin (175) as well as a direct effect of 
cyclosporine on smooth muscle tone. 
Cyclosporine nephrotoxicity may be manifest in
stages after transplantation as transient acute renal failure. 
The increase io serum creatinine is b ef, often associated 
with elevated cyclosporine l vels, an 
tions in the dose 
vement in cardiac ou 
higher serum creatinine at time of 
greater isk of acute nephrotoxicity. 
common clinical syndrome of renal injury is the chronic 
nephropathy noted above. This syndrome is principally 
characterized bya gradual increase but eventual plateau in 
serum creatinine l vels (169-171,176). Theincrease inserum 
48 MILLER ET AL. 
JACC Vol. 22, No. 1 
TASK FORCE 5 July 1993:~~64 
creatinine is assca-iated with a disproportionate azotemia, 
hyperkalemia, ncreased uric acid levels (due to decreased 
fractional excretion), mild proteinuria, (usually less than 
1 g/24 h), and a decreased fractional excretion of sodium 
which is unique to nephrotoxins (165,166). There are case 
reports of patients progressing to end-stage r nal failure and 
requiring dialysis (166,168), but this is very uncommon with 
the doses of cyclosporine used today, Withdrawal ofcyclo- 
sporine or dose reductions are associated with improve- 
ments in serum creatinine even in patients with morphologic 
evidence of cyclosporine toxicity (171,t72), although serum 
creatinine may overestimate glomeruiar filtration rate (177). 
There are no known treatments that are uniformiy effective 
in preventing or reversing the nephrotoxic effects of cyciospo- 
tine in heart ransplant recipients, although administration of a
prostaglandin E, analogue has decreased the development of 
nephrotoxici!y in renal transp -iant patients (178) it is generaliy 
agreed that cbse monitoring of cyciosporine ievels is critically 
Ltportant to iirnlt progressive d cline in renai fur&on (i76). 
Another possible strategy I :.- +r\ rinhr &c ~~~&-$~~~a &$‘y&Jsp+ pS LU ULI5J 
tine postoperatively in patients athigh risk for nephrotoxicity. 
There are many drugs that alter cycbsporine i vels or have 
additive nephrotoxicity in combination with cyclosporine. It is 
generally recommended that initiation or wkhdrawal of any 
drug be done -with caautron and ey~.~~~~~,..._ __ -‘-nrn~np levels checked and 
dosage modified to maintain levels in the therapeutic/nontoxic 
range. 
Hypertension is a common complication ofcyclosporine 
therapy (179,180) occurring in up to 50% to 90% of heart 
transplant recipients (I? 181-182). Cyciosporine-associated 
hypertension typically develops within weeks to months of 
transplantation ndependent of the development of nephro- 
toxicity but may also develop years after transplant in 
association with worsening renal function. ‘This form of 
hypertension does not appear to be influenced by the demo- 
graphic haracteristics a sociated with essential hyperten- 
sion, such as age, race, sex or body weight Interestingly, 
the nocturnal decrease in blood pressure that is typical of 
patients with essential hypertension is reversed in these 
patients and blood pressure isoften higher during the night 
(183), although this finding may normalize with time after 
transplantation. 
One of the most frequently cited mechanisms of cycio- 
sporine-associated hypertension is its inherent nephrotoxicity 
(179,184). However, the increasa in blood pressure does not 
correlate with the change in renal function. Other possible 
mechanisms include volume xpansion (185), increased sym- 
pathetic tone (Ma), increased ndotheiin levels (187) and to a 
lesser extent, stimulation of the renin-angiotensin system 
(188,189). White renal vasoconstriction has been well docn- 
mented, this effect is not uniform since forearm blood flow and 
reactive hyperemia remain ormal (190-192). 
Many different agents have been used in the treatment of 
hypertension after heart transplantation, but the effective- 
ness of any single or comhit\c?+*m tL --. L-- .- ’ a,_.__iiv.r il laPy IIC~Z, nutoeen studie 
in prospective randomized trials. Anecdote xperience with 
calcium blockers, converting enzyme inhibitors, beta blockers, 
and alpha blockers suggest that all have been used with varying 
success, either alone or in combination. Diuretics must be used 
with caution since vohtme depletion and subsequent neurohor- 
mortal vasoconstrictor effects may irX$e an adverse ffect on 
renal function and cardiac hemodynamics. 
Hyperiipidemia h s been reported in60% to 80% of heart 
transplant recipients reated with triple-dr!!g immunosuppres- 
sion regimens consisting of cyclosporine. azathioptine and 
prednisone (192-!96). Elevations in cholesterol levels have 
beea ieported as earl; v’ as 3 weeks after transplantation and 
almost ah patients who develop hypercholesterolemia do so 
*within the !st 6 to !8 months after transplantation. The mag 
&de oT Increase n total cholesteroi is variable but appear-s ?o 
be modest, rangmg ftom an aver&de of 30 iu 80 n&d1 over 
pretransplant levels. If left untreated, however: much higher 
levels have been observed. The dev~~o~rne~t of hypercholes- 
teroiemia appears tobe dependent ona large number of diverse 
mechanisms (1973 including a prior history of ischemic heart 
disease , preexisting lipid abnormal&s, cumulative dose of 
corticosteroids (198) and to a lesser extent cyciosporine (199). 
Withdrawal of corticosteroids has been associated with tower Y____ S .._a 
cholesterol levels, but only if withdrawn withrn weeks after 
transplantation (200,201). 
The treatment tif byperiiyidemia h s foccscd on weight 
loss, exercise, and lower doses of steroids and cyciosporine. 
Several centers have reported. favorable experience with the 
lipid lowering agents gern35, rsr~. *no: and low-dose iovastatin 
(202), aithotigh rhabdomyoiysis has been reported with 
iovastatin. These agents result in short-term reductions in 
choiesteroi ranging from 20% to 60 mg/ltKi ml. Jt is not 
certain whether aggressive therapy with cholesterol ioweriug 
agents will have any salutary effect 08 the incidence of 
a!iC&t coronary artery d’ tsease, myocardia? events, graft 
failure or survival. This relation requires further investiga- 
tion because of the expense and possible risk of additional 
pharmacologic therapy. 
Osteoporosis 
Osteoporosis is a common complication ofcorticosteroid 
therapy (203,204) occurring in up to 10% of heart ransplant 
recipients followed long term (205,206). dommon clinical 
manifestations i clude back pain due to vertebral compres- 
sion fractures and avascular necrosis of weight-bearing 
joints, often leading to surgical joint replacement. Osteo- 
porosis i  thought to be primarily a result of cumulative steroid 
dose but other isk factors include older age (205) lower bone 
mass before transplantation (206), postmenopausal tatus in 
female recipients (207) and possibly the use of cyciosporine 
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days) doses of testosterone or estrogen (21 li, vi 
oride, anabolic steroids, bisphos 
was Jofine$ pr J(lc;r, =0re &q ;&_..t La...:.; i1 .>;;;"' /,%I *\ A.3 -vi lan, I\iG.UI UU"j nc.jm \!A!‘+t), by i 
io Z vears after heart transpiantation. Most weight gain _a 
occurred in the 1st year afte: heart aranspiant surgery with 
httie change thereafter; 2~1 ’ _ _.._ii.. u .o men and i;v’omen VVW$ sqcr;;ij 
affected (2i4,XS). Patients who are obese before trans$an= 
tation are at hioh riqk of remaining obese postoperatively U-B’- __<.. 
(2I5,216j although a family Ristcry of dxsity is ~5; an 
in&pen&tit l-i!& hric?r (217). 
Biiiary hci disease appears to be the most common 
gastrointestinal complication following cardiac tran@anta- 
tion (218,219). Cyciosporine may affect bile metabo!ism b:~ 
decreasing biie saii secreuon, theiet‘ure causing cholestmis, 
leading to galh&oe formation (219--221). Heart transplant 
patients who undergo elective cholecystectomy appear to 
have little ,mortdity. However, patients requiring urgent 
cholecystectomy have been reported to have mortality rates 
as high as 40% (222-224). 
Pancreatitis has been reported to occur In 2% to 18% of 
patients following heart rr~nsplailiaiirj~~ ad ~maj; $62 as&- 
ated with high morbidity and mortality when serrere 
(220,225). The pancreatitis appears to be caused by periop- 
erative splanchnic hypoperfusion (exacerbated by vasopres- 
sots) and the presence ofpreexisting pancreatic disease. The 
use of azathioprine, which is a known cause of pancreatitis 
(223, may need to be avoided if this complication develops 
late following cardiac transplantation. 
Clinical evidence of major abdominal disease may be 
obscured in patients on corticosteroids (226). The absenoe of
leukocytosis, abdominal guarding and rebound may lead to a 
delay in diagnosis, thereby increasing the risk of mo 
and mortality. Thus, aggressive management of intra 
inal disease is essential, including adequate vohtme replace- 
ment, use of stress doses of corticosteruids when necessary 
and maintenance of adequate cyclosporine l vels. 
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Over the past decade heart ransplantation has evolved from 
a rarely performed experimental procedure to an accepted 
therapy for end-stage heart disease. Despite the escalation i  
the number of procedures and the progressive improvement 
in postoperative outcome as described by Task Force I, two 
formidable obstacles continue to challenge the success of 
heart ransplantation. 
Contemporary immunosuppressive strategies have re- 
duced the incidence of acute rejection but have severe 
limitations. These include lack of specificity, inability to 
reduce the risk of cardiac allograft vasculopathy (the major 
factor limiting long-term recipient survival), significant tox- 
icity and an increased risk of opportunistic infections and 
malignancy. 
The understanding of the immune respouse at increas- 
ingly fundamental levels and the ability to combine data from 
in vitro assays of immune function with information from in 
vivo models of organ transplantation and autoimmune dis- 
ease have enabled rapid advances in the discovery and 
development of new immunosuppressive modalities. These 
include I) the discovery of new molecules that affect he 
response of immune cells to antigenic stimuli by inhibiting 
either cytokine synthesis, the action of cytokines and growth 
factors, deoxyribonucleic acid (DNA) synthesis or cell mat- 
uration; 2) the introduction of less toxic and more selective 
monoclonal ntibodies targeting cell subsets, adhesion mol- 
ecules or cytokines mediating the rejection process; 3) the 
use of therapeutic irradiation of the immune system; 4) the 
use of apheresis procedures; 5) the development of gene 
manipulation strategies directed at alteration or suppression 
of alloantigens. 
Although these advances will improve the outcome of 
heart ransplantation, none of them is a solution for the most 
pressing problem facing organ transplantation: the critical 
shortage of domor organs. Because the pool of potential 
candidates continues to expand while donor organs remain 
critically scarce, the discrepancy between the number of 
patients who would benefit from heart ransplantation a d 
the number of patients who actually receive a transpianr 
continues to increase at an alarming rate. It is estimated tha? 
as many as 30% of patients awaiting heart rausplantation die
before a suitable donor organ becomes available. The severe 
shortage of donor organs emphasizes the crucial need for 
identifying alternatives toallotransplantation. Potential so- 
lutions include 1) xenotransplantation, 2) the application of
transformed skeletal muscle, and 3) mechanical ssist and 
replacement devices. 
This report will Laddress both future developments in
immunosuppression thatmay help optimize the use of scarce 
